Anupam Rama
JPMorgan Chase & Co, Research Division
Welcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I am one of the senior biotech analysts here at JPMorgan. I’m joined by my squad, Rati Pinge, Priyanka Grover and Joyce Zhou.
Our next presenting company is Enanta, and presenting on behalf of the company, we have CEO, Jay Luly.
Jay Luly
President, CEO & Director
Thank you, Anupam. Before I begin, I want to remind you, I’ll be making some forward-looking statements. For a summary of the risks associated with these statements, please see our filings on sec.gov and on our website.
For those of you who are less familiar with Enanta, we are a virology and immunology company. Our roots originally were in virology and even deeper in hepatitis C, in the early days of hepatitis C, where we helped bring forward two products with AbbVie to market. Our key program there was hep C protease. And we invented glecaprevir, which is a part of the hep C drug called MAVYRET, which has cured well over 1 million patients chronic hepatitis C.
We moved beyond the liver virology several years ago and got into respiratory virology with RSV being our first target there. Viewing the high unmet need, the virus has been characterized for more than 6 decades. But to this date, nobody has brought forward a safe and effective treatment for the virus. More recently, there have been vaccines but even those have limitations and there’s an incredible vulnerable population in the world that we
Credit: Source link
